2023-2030 年葡萄膜炎全球市場

市場概覽

葡萄膜炎的全球市場規模預計到 2022 年將達到 4.56 億美元，到 2030 年將達到 8.37 億美元，預測期內（2023-2030 年）的複合年增長率為 4.8%。

葡萄膜炎是一種眼睛炎症，會影響眼球內的中間組織層。 它主要發生在20至50歲的人群中。 葡萄膜炎是一個嚴重的問題，有時會導致視力喪失。

市場動態

推動全球葡萄膜炎市場發展的主要因素是由於青光眼和白內障等眼科疾病發病率的增加導致對葡萄膜炎的需求增加，提高認識活動，導致新藥開發和新產品推出。這是技術的進步。

製藥公司不斷增加的產品線和不斷提高的技術進步導致新藥的開發預計將推動市場的增長。

葡萄膜炎市場的驅動因素包括技術進步不斷加快、人口老齡化、研發投資激增、青光眼、白內障和 AMD 等眼科疾病的增加，以及對尖端技術和改進醫療基礎設施的需求在新興市場，它是由使用的新產品的改進驅動的。

葡萄膜炎藥物廣泛用於治療目的。 這些設備越來越多地被採用，導致政府的舉措和資金不斷增加。 這些資金將幫助生產葡萄膜炎藥物，例如眼藥水、注射劑、藥片和植入物。 隨著患有這些眼病的患者數量不斷增加，這些藥物的市場正在全球範圍內擴大。 此外，預計主要參與者提供的技術先進的產品也將在市場增長中發揮重要作用。

與這些葡萄膜炎治療相關的各種新產品發布、研究和提高認識活動正在促進市場的增長。 例如，2022 年 11 月 1 日，Alimera Sciences 這家專注於患者維持視網膜健康和更好視力的製藥公司宣布，其位於愛爾蘭的歐洲子公司 Alimera Sciences Europe 將宣布獲得 ILUVIEN（ fluocinolone acetonide 玻璃體內植入物），一種緩釋眼內植入物，通過其分銷合作夥伴 Medis 用於治療非感染性葡萄膜炎。

高昂的治療成本和高副作用風險預計會阻礙市場增長。

關於批准用於葡萄膜炎的藥物的嚴格規章制度是阻礙葡萄膜炎市場增長的主要因素。 不同的要求，必須滿足臨床試驗，導致這些藥物的總體成本增加。 與這些治療相關的高成本會阻礙增長。

此外，與這些藥物副作用相關的高風險也限制了市場增長。 市場召回也是製約市場增長的主要因素。 由於植入物洩漏和並發症，已經有幾次召回事件。

COVID-19 影響分析

疫情正在對全球金融預期、運營和危機應對策略產生負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID，葡萄膜炎市場遭受了巨大損失。 主要製造商已經啟動了各種研究和臨床試驗。 世界各地正在開展各種舉措、產品發布、合作和合併，推動市場增長。 例如，2022 年 10 月 17 日，Kiora Pharmaceuticals, Inc. 公佈了 KIO-100（原 PP-001）治療非感染性葡萄膜炎（一種治療眼部炎症性疾病）的 1 期試驗結果，顯示了其可能性。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

• 市場影響因素
  • 司機
    • 增加製藥公司的產品線
    • 引領新藥開發的技術進步
  • 約束因素
    • 高昂的治療費用
    • 副作用風險高
  • 商機
  • 影響分析

第五章行業分析

• 波特的五力分析
• 供應鏈分析
• 定價分析

第 6 章 COVID-19 分析

• COVID-19 市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 期間的價格動態
• 供需範圍
• 大流行期間與市場相關的政府舉措
• 製造商的戰略舉措
• 總結

第 7 章葡萄膜炎的類型

• 前葡萄膜炎
• 中間葡萄膜炎
• 後葡萄膜炎
• 全葡萄膜炎

第8章藥物

• 皮質類固醇
  • 倍他米松
  • 地塞米松
  • 可的松
  • 去炎松
  • 甲潑尼龍
• 抗風濕藥
  • 黴酚酸酯
  • 環孢菌素
  • 硫唑嘌呤
  • 他克莫司
• Cycloprentic/散瞳
  • 托□卡胺
  • 環噴托酯
  • 去氧腎上腺素
  • 促生長素
  • 阿托品
• 免疫調節療法
  • 硫唑嘌呤
  • 甲氨蝶呤
  • 黴酚酸酯
  • 環孢菌素
• 生物療法
  • 英夫利昔單抗
  • 阿達木單抗
  • 達珠單抗
  • 干擾素-ALPHA
• 抗病毒劑
  • 阿昔洛韋
  • 伐昔洛韋
• 其他

第9章藥物形式

• 眼藥水
• 藥丸
• 注射
• 植入

第 10 章最終用戶

• 醫院藥房
• 零售藥房
• 在線藥店

第11章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第12章競爭格局

• 主要發展和戰略
• 公司股票分析
• 產品基準
• 值得關注的主要公司名單

第13章公司簡介

• 諾華公司
  • 公司簡介
  • 產品組合和說明
  • 主要亮點
  • 財務摘要
  要

Market Overview

The global uveitis market size was valued at US$ 456 million in 2022 and is estimated to reach US$ 837 million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Uveitis is an eye inflammation, which affects the middle layer of the tissue in the eyewall. The majority of the alter lie in the population ages of 20 to 50 years. Uveitis can sometimes be a serious issue that can also lead to loss of vision.

Market Dynamics

The major factors driving the global uveitis market are the rising demand for uveitis owing to increasing incidences of ophthalmic disorders such as uveitis glaucoma and uveitis cataract, surging awareness initiatives, advancements in technologies leading to the development of new drugs and novel product launches.

The increasing product pipeline of pharma companies and rising technological advancements leading to the development of new drugs are expected to drive the market's growth.

The uveitis market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of ophthalmic disorders such as uveitis glaucoma, uveitis cataract, AMD and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The uveitis medications are used widely for treatment purpose. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce uveitis medication products such as eye drops, injections, pills or implants. The market for these medications is increasing worldwide due to the enhanced number of these ophthalmic disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these uveitis medications contribute to the market's growth. For instance, in November 1, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) which is a sustained release intravitreal implant indicated for non-infectious uveitis, via Medis Pharmaceutical Company, its distribution partner.

High cost associated with the treatment and high risk of side effects are expected to hamper the market's growth.

Strict rules and regulations for the approval of medications utilized for uveitis is the major factor hindering the growth of the uveitis market. Various requirements, clinical trials must be fulfilled, leading to an increase in the overall cost of these medications. The high cost associated with these treatments is likely to hinder the growth.

High risk related to side effects of these medications is also limiting market's growth. Market recalls are also a leading factor restraining the growth of the market. Several recalls are taking place due to leakage or complications in implants.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The uveitis market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in October 17, 2022, Kiora Pharmaceuticals, Inc. announced its results from KIO-100 (formerly PP-001) Phase 1 study, showing its potential for non-infectious uveitis, an ophthalmic inflammatory disease treatment.

Segment Analysis

The anterior uveitis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The anterior uveitis segment is the highest market holder in the global uveitis market. The global uveitis market is segmented based on disease type as anterior uveitis, intermediate uveitis, posterior uveitis and pan uveitis. The anterior uveitis segment is the largest market shareholder due to its increasing number of incidences globally, increasing technological advancements and novel product launches.

Anterior uveitis is the most common kind of uveitis which mostly affects the ciliary body and the inside of the front of eye (between the iris and the cornea). It is also also known as iritis. Anterior uveitis can be caused due to a trauma to the eye, like getting hit in the eye or having a foreign particle in the eye. It is also linked with common health problems including syphilis, rheumatoid arthritis, tuberculosis and viral (herpes simplex). Its symptoms include blurred vision, red or inflamed eye, small, irregular-shaped pupil and sensitivity to light.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in March 28, 2022, Bausch + Lomb, Bausch Health Companies' eye health business and Clearside Biomedical, Inc. a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS) announced the commercial launch of XIPERE (triamcinolone acetonide injectable suspension) in U.S., the first therapy which got approval for suprachoroidal use by the U.S. Food and Drug Administration (FDA) for the macular edema associated with uveitis treatment.

Geographical Analysis

North America holds the largest market share in the global uveitis market.

North America dominates the global uveitis market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of uveitis medications in several ophthalmic conditions like uveitis glaucoma or uveitis cataract, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the uveitis market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in August 8, 2022, Clearside Biomedical, Inc., a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS), announced about entering into a sale agreement with HealthCare Royalty Partners.

Competitive Landscape

The uveitis market is highly competitive with local and global companies' presence. Novartis Inc., AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in September 23, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced its agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), to support and provide ILUVIEN (fluocinolone acetonide intravitreal implant) intravitreal implant for "A randomized clinical trial evaluating fluocinolone acetonide intravitreal implants or intravitreal faricimab injections vs due to Radiation Retinopathy visual acuity loss prevention observation.

Novartis AG

Overview: Novartis is engaged in discovering, developing, manufacturing, and selling a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Durezol: It is a topical corticosteroid which is indicated for pain and inflammation treatment linked with ocular surgery and endogenous anterior uveitis treatment.

Key Development: In June 17, 2022, Sandoz, a generic and biosimilar medicines provider, announced about application acceptance for high concentration formulation of its biosimilar Hyrimoz (adalimumab) by the European Medicines Agency (EMA) for regulatory review. The application covers all indications, including rheumatoid arthritis, uveitis, Crohn's disease, ulcerative colitis and plaque psoriasis

The global uveitis market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing product pipeline of pharma companies
    • 4.1.1.2. Rising advancements in technologies leading to the development of new drugs
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost associated with treatment
    • 4.1.2.2. High risk of side effects
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Supply Chain Analysis
• 5.3 Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Uveitis Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 7.1.2. Market Attractiveness Index, By Uveitis Type
• 7.2. Anterior Uveitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Intermediate Uveitis
• 7.4. Posterior Uveitis
• 7.5. Pan Uveitis

8. By Medications

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 8.1.2. Market Attractiveness Index, By Medications
• 8.2. Corticosteroids *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.2.3. Bethamethasone
  • 8.2.4. Dexamethasone
  • 8.2.5. Cortisone
  • 8.2.6. Triamcinolone
  • 8.2.7. Methylprednisolone
• 8.3. Anti-Rheumatic Drugs
  • 8.3.1. Mycophenolate
  • 8.3.2. Cyclosporine
  • 8.3.3. Azathioprine
  • 8.3.4. Tacrolimus
• 8.4. Cycloplegic-Mydriatic Drugs
  • 8.4.1. Tropicamide
  • 8.4.2. Cyclopentolate
  • 8.4.3. Phenylephrine
  • 8.4.4. Homatropine
  • 8.4.5. Atropine
• 8.5. Immunomodulatory Therapy
  • 8.5.1. Azathioprine
  • 8.5.2. Methotrexate
  • 8.5.3. Mycophenolate Mofetil
  • 8.5.4. Cyclosporine
• 8.6. Biological Therapy
  • 8.6.1. Infliximab
  • 8.6.2. Adalimumab
  • 8.6.3. Daclizumab
  • 8.6.4. Interferon-Alfa
• 8.7. Anti-Viral Drugs
  • 8.7.1. Aciclovir
  • 8.7.2. Valaciclovir
• 8.8. Others

9. By Medication Form

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 9.1.2. Market Attractiveness Index, By Medication Form
• 9.2. Eye Drops *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Pills
• 9.4. Injections
• 9.5. Implants

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Products Benchmarking
• 12.4. List of Key Companies to Watch

13. Company Profiles

• 13.1. Novartis AG *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. AbbVie
• 13.3. Johnson & Johnson Services, Inc.
• 13.4. Amgen
• 13.5. Alimera Sciences
• 13.6. Bausch & Lomb Incorporated.
• 13.7. Kiora Pharmaceuticals, Inc.
• 13.8. Santen Pharmaceutical Co., Ltd.
• 13.9. EyePoint Pharmaceuticals, Inc.
• 13.10. Clearside Biomedical

LIST NOT EXHAUSTIVE

14. Global Uveitis Market - DataM

• 14.1. Appendix
• 14.2. About Us and Medications
• 14.3. Contact Us